Literature DB >> 11377312

Impact of medical therapy on transurethral resection of the prostate: a decade of change.

C S Borth1, D T Beiko, J C Nickel.   

Abstract

OBJECTIVES: To assess whether medical therapy has delayed the need for eventual transurethral prostatectomy (TURP), causing a shift in the population characteristics of men undergoing TURP (ie, older, more comorbidities, more advanced disease), resulting in more complications and poorer outcomes. The introduction of medical therapy for symptomatic benign prostatic hyperplasia (BPH) during the past decade may have changed the indications for TURP.
METHODS: All patients who underwent TURP for symptomatic BPH at our institution in 1988 (before general introduction of medical therapy for BPH) and 1998 (medical therapy the primary initial therapy for BPH) were reviewed. We compared the two groups with respect to the total number of TURPs, indications for surgery, patient age, health status, weight of resected tissue, and preoperative and postoperative complications.
RESULTS: Despite a 16% increase in men at risk of BPH-related events, a 60% decrease in the total number of TURPs performed for symptomatic BPH occurred in 1998 (n = 64) compared with 10 years earlier (n = 157). No significant difference was found in age between the two groups, and no increase in comorbid status was observed. Previous medical management had failed in 36% of men who required TURP in 1998. A significantly higher percentage of patients presented in acute urinary retention (55%) and upper tract obstructive uropathy (12.5%) in 1998 compared with 1988 (23% acute urinary retention and 1.3% obstructive uropathy). Patients in 1998 were healthier, underwent smaller resections, had their catheters removed earlier, and were discharged home earlier. Although they were more likely to be discharged home with a catheter in situ, no significant difference was observed in the incidence of postoperative complications.
CONCLUSIONS: There has been a dramatic decrease in the number of TURPs performed for symptomatic BPH at our institution since the advent of medical therapy. The proportion of TURP patients presenting with urinary retention and hydronephrosis increased, but the average age, medical comorbidities, operative parameters, and postoperative complications have not significantly changed.

Entities:  

Mesh:

Year:  2001        PMID: 11377312     DOI: 10.1016/s0090-4295(01)01018-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  TURP in the new century: an analytical reappraisal in light of lasers.

Authors:  Assaad El-Hakim
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

Review 2.  Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?

Authors:  Fabrizio Presicce; Cosimo De Nunzio; Andrea Tubaro
Journal:  Curr Urol Rep       Date:  2017-09       Impact factor: 3.092

3.  Changing patients' profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspective.

Authors:  Mohamed A Elkoushy; Ahmed M Elshal; Mostafa M Elhilali
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 4.  Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review.

Authors:  Fabrizio Presicce; Cosimo De Nunzio; Andrea Tubaro
Journal:  Curr Urol Rep       Date:  2018-07-09       Impact factor: 3.092

5.  Changes in surgical strategy for patients with benign prostatic hyperplasia: 12-year single-center experience.

Authors:  Yu Seob Shin; Jong Kwan Park
Journal:  Korean J Urol       Date:  2011-03-18

6.  Impact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades.

Authors:  Se Young Choi; Tae-Hyoung Kim; Soon Chul Myung; Young Tae Moon; Kyung Do Kim; Young Sun Kim; Hye-Ryoun Kim; In Ho Chang
Journal:  Korean J Urol       Date:  2012-01-25

7.  A Review of Aging and the Lower Urinary Tract: The Future of Urology.

Authors:  Hisae Nishii
Journal:  Int Neurourol J       Date:  2021-12-31       Impact factor: 2.835

8.  Benign prostatic hyperplasia and subsequent risk of bladder cancer.

Authors:  D Kang; A P Chokkalingam; G Gridley; O Nyren; J E Johansson; H O Adami; D Silverman; A W Hsing
Journal:  Br J Cancer       Date:  2007-05-01       Impact factor: 7.640

9.  Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study.

Authors:  Do Kyung Kim; Jae Joon Park; Won Jae Yang; Seung Whan Doo; Jae Heon Kim; Yun Seob Song
Journal:  Prostate Int       Date:  2021-09-03

10.  Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea.

Authors:  Jung Ki Jo; Sung Ho Shinn; Kyu Shik Kim; Hong Sang Moon
Journal:  Int Neurourol J       Date:  2021-01-27       Impact factor: 2.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.